UMMS Team Publishes In Vitro, In Vivo Data on Oral siRNA-Delivery Tech
April 30, 2009
UMMS Team Publishes In Vitro, In Vivo Data on Oral siRNA-Delivery Tech
The technology, called glucan-encapsulated siRNA particles, or GERPs, has been exclusively licensed by RXi Pharmaceuticals for use in developing RNAi-based therapeutics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar
March 26, 2009 / Gene Silencing News - IP Update
April 23, 2009 / Gene Silencing News - MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
March 26, 2009 / Gene Silencing News - Strands
March 19, 2009 / Gene Silencing News - UMMS, RXi Researcher Wins $5M NIH Grant to Develop Oral RNAi Delivery Tech
October 1, 2009 / Gene Silencing News